Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13185397 | 0.84 | POLB (0.37) | POLBCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10037571 | 0.84 | POLB (0.37) | POLBCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13448309 | 0.83 | POLB (0.35) | POLBCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL327611 | 0.82 | SMN1; SMN2 (0.35) | POLBCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12107536 | 0.82 | CYP1A2 (0.43) | POLBCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL11955679 | 0.82 | POLB (0.32) | POLBSLC1A2 | |
| SCHEMBL12507623 | 0.81 | ACACB (0.36) | POLBSLC1A2 | |
| SCHEMBL10310647 | 0.80 | POLB (0.35) | POLBCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12505905 | 0.80 | HTT (0.35) | POLBHTTMAPK1 | |
| SCHEMBL12421899 | 0.79 | SLC1A2 (0.47) | POLBCYP2C9ALDH1A1SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120244597-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245289-A1 | POLYMER-FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2012-09-27 | — | — | US | disclosed |
| US-8273339-B2 | Polymer-based compositions and conjugates of antimicrobial agents | NEKTAR THERAPEUTICS (US) | 2012-09-25 | — | — | US | disclosed |
| US-8247536-B2 | Factor VIII compositions | NEKTAR THERAPEUTICS (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120178692-A1 | DOSAGE FORMS OF POLYMER-FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120100096-A1 | CONJUGATES PF SMALL-INTERFERING NUCLEIC ACIDS | NEKTAR THERAPEUTICS (US) | 2012-04-26 | — | — | US | disclosed |
| US-20110318322-A1 | Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer | NEKTAR THERAPEUTICS (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110237524-A1 | POLYMER CONJUGATES OF AOD-LIKE PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110171162-A1 | POLYMER CONJUGATES OF THYMOSIN ALPHA 1 PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110165112-A1 | POLYMER CONJUGATES OF C-PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110165113-A1 | POLYMER CONJUGATES OF V681-LIKE PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110165111-A1 | POLYMER CONJUGATES OF NESIRITIDE PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110135623-A1 | Conjugates of a Cholinesterase Moiety and a Polymer | NEKTAR THERAPEUTICS (US) | 2011-06-09 | — | — | US | disclosed |
| US-7858749-B2 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010021720-A1 | CONJUGATES OF SMALL-INTERFERING NUCLEIC ACIDS | NEKTAR THERAPEUTICS (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135623-A1 | Conjugates of a Cholinesterase Moiety and a Polymer | BCHE, ACHE, DNPEP | POLB 1321/4885CYP1A2 964/4885CYP3A4 645/4885 |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | POLB 563/4885CYP1A2 1712/4885CYP3A4 1578/4885 |
| US-20110237524-A1 | POLYMER CONJUGATES OF AOD-LIKE PEPTIDES | NGLY1, OCIAD1, TAP1 | POLB 2279/4885CYP1A2 3126/4885CYP3A4 2691/4885 |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | F9, F13A1, F13B | POLB 1496/4885CYP1A2 3352/4885CYP3A4 3085/4885 |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | POLB 813/4885CYP1A2 4445/4885CYP3A4 4604/4885 |
| US-20110165111-A1 | POLYMER CONJUGATES OF NESIRITIDE PEPTIDES | NGLY1, IAPP, NPSR1 | POLB 4193/4885CYP1A2 3996/4885CYP3A4 2561/4885 |
| US-20110165112-A1 | POLYMER CONJUGATES OF C-PEPTIDES | IAPP, GCG, INSR | POLB 3605/4885CYP1A2 4674/4885CYP3A4 4081/4885 |
| US-20120178692-A1 | DOSAGE FORMS OF POLYMER-FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | POLB 685/4885CYP1A2 653/4885CYP3A4 454/4885 |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | POLB 2387/4885CYP1A2 4643/4885CYP3A4 4045/4885 |
| US-20120245289-A1 | POLYMER-FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | POLB 495/4885CYP1A2 1857/4885CYP3A4 1601/4885 |
| US-20110171162-A1 | POLYMER CONJUGATES OF THYMOSIN ALPHA 1 PEPTIDES | TMSB4X, TMSB10, TAP1 | POLB 2957/4885CYP1A2 3304/4885CYP3A4 2295/4885 |
| US-20110165113-A1 | POLYMER CONJUGATES OF V681-LIKE PEPTIDES | NGLY1, VIP, DNPEP | POLB 2466/4885CYP1A2 4660/4885CYP3A4 4046/4885 |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | POLB 2714/4885CYP1A2 4874/4885CYP3A4 4751/4885 |
| US-20120100096-A1 | CONJUGATES PF SMALL-INTERFERING NUCLEIC ACIDS | SLC19A1, FOLR1, SLC46A1 | POLB 130/4885CYP1A2 4678/4885CYP3A4 4711/4885 |
| US-20110318322-A1 | Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer | GAA, MAN2B1, GBA1 | POLB 936/4885CYP1A2 4362/4885CYP3A4 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.